BioLineRx

NASDAQ BLRX
$0.62 -0.03 -4.52%
Today share price
Israel
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 14 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

44.70M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

50.74M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

1.45
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

72.44M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-60.70 %

Upcoming events BioLineRx

All events
No upcoming events scheduled

Stock chart BioLineRx

Stock analysis BioLineRx

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

-0.70 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

3.38 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

-1.22 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

-0.15 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

-483.40 7.67

Price change BioLineRx per year

1.40$ 4.23$
Min Max

Summary analysis BioLineRx

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure BioLineRx

Revenue and net income BioLineRx

All parameters

Stock news BioLineRx

All news

BioLineRx Shares Rise 12% After Licensing Agreement for Motixafortide

BioLineRx Shares Rise 12% After Licensing Agreement for Motixafortide

BioLineRx Shares Climb 22% After FDA Approves Aphexda With Filgrastim

BioLineRx Shares Climb 22% After FDA Approves Aphexda With Filgrastim

BioLineRx Gets FDA Approval for Aphexda With Filgrastim

BioLineRx Gets FDA Approval for Aphexda With Filgrastim

ADRs End Higher, Alibaba and BioLineRx Trade Actively

ADRs End Higher, Alibaba and BioLineRx Trade Actively

ADRs End Lower; BioLineRx, Can-Fite BioPharma Trade Actively

ADRs End Lower; BioLineRx, Can-Fite BioPharma Trade Actively

ADRs End Higher; Ascendis Pharma, BioLineRx Trade Actively

ADRs End Higher; Ascendis Pharma, BioLineRx Trade Actively

ADRs End Mostly Lower; Anheuser-Busch, BioLineRx Trades Actively

ADRs End Mostly Lower; Anheuser-Busch, BioLineRx Trades Actively

ADRs End Higher; BioLineRX, SAP Among Companies Actively Trading

ADRs End Higher; BioLineRX, SAP Among Companies Actively Trading

BioLineRx Shares Up After Results From Motixafortide Study

BioLineRx Shares Up After Results From Motixafortide Study

About company BioLineRx

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.
Address:
Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
Company name: BioLineRx
Issuer ticker: BLRX
ISIN: US09071M2052
Country: Israel
Exchange: NASDAQ
Currency: $
IPO date: 2011-07-25
Sector: Healthcare
Industry: Biotechnology
Site: https://www.biolinerx.com

On which stock exchange are BioLineRx (BLRX) stocks traded?

BioLineRx (BLRX) stocks are traded on NASDAQ.

What is the ticker of BioLineRx stocks (BLRX)?

The stock ticker of BioLineRx’s stocks or in other words, the code is BLRX. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does BioLineRx (BLRX) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, BioLineRx (BLRX) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are BioLineRx (BLRX) stocks traded?

BioLineRx (BLRX) stocks are traded on the NASDAQ exchange in dollars.

What is the price of BioLineRx (BLRX) stocks today?

The current price of BioLineRx stocks on 16.05.2024 is 0.617 dollars. per share.

What is the dynamics of BioLineRx (BLRX) stocks from the beginning of the year?

BioLineRx (BLRX) quotes have increased by -59.67% from the beginning of the year up to 0.617 dollars. per 1 stocks.

How much did BioLineRx (BLRX) stocks increase in мае 2024?

This month BioLineRx (BLRX) quotes have increased by -8.2% to 0.617 dollars. per share.

How much are BioLineRx (BLRX) stocks worth?

Today, on October, 16.05.2024 BioLineRx’s (BLRX) stocks cost 0.617 dollars..

What is the market capitalization of BioLineRx (BLRX)?

Capitalization is the market value of BioLineRx (BLRX) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 16.05.2024, the market capitalization of BioLineRx (BLRX) is estimated at about 44695034 dollars.